🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Immunotherapy shows sex bias—men respond better; women face more severe AEs. Understanding sex hormones, chromosomes, and epigenetics in immunity could lead to tailored immuno-oncology strategies. #Cancer #Immunotherapy #Oncology OncoAlert Nature Reviews Cancer

On behalf of all the Trustees, volunteers and supporters of METUPUK, we would like to offer our heartfelt congratulations to our Founder, Jo Taylor, for being awarded the British Empire Medal in The King's New Year Honours List 2025. A much deserved recognition for years of work

One of the most important electrolyte imbalances in cancer patients - Hypomagnesemia Keep a lookout & test when indicated! A quick run through of causes of ⬇️ Mg in Ca pts - especially keep in mind when using 💊EGFRibs 💉Platins 💊TKIs 💉Anti HER2 Dr Amol Akhade #cancer #oncology

Money slide💰: Snapshot of survival data for all 1st line CDK4i trials in advanced breast cancer

Key ICI trials in metastatic melanoma Journal of Clinical Oncology

Systemic Glucocorticoid Dose Equivalents.

Management of Locally Advanced Rectal Cancer: ASCO Guideline | Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

And then There were TWO. Nice summary slide to Compare Sacituzumab govitecan-hziy and Sacituzumab tirumotecan in TNBC based upon recently published data of Later in Nature. Do note The difference in structure and efficacy of both ADCs. nature Oncology Brothers OncoAlert #bcsm

Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer 🔍42 pts, 3 neoadjuvant cycles and 5 adjuvant cycles Atezo+T+ XELOX vs T+XELOX pCR➡️38.1 vs 14.3% MPR➡️42.9 vs19.0% R0 res➡️95.2 vs 90.5% jamanetwork.com/journals/jamao…

The first abcd retreat of the year is on this weekend! A lovely group of people & we’ve all bonded well already. Emotional stories, support & laughs. A mixture of primary & metastatic breast cancer patients getting to know each other. A nice meal at @theoldbellinndelph It’s

Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† 🔹️ICI for dMMR/MSI-H 🔹️Watch-and-wait approach 🔹️TNT/neoadj ChT 🔹️RT dose 🔹️Restaging timing 🔹️Local excision annalsofoncology.org/article/S0923-…

One week to #ASCO25. Which will be an unprecedented ASCO for breast oncologists. Treatment algorithms will change for ALL disease subtypes. ADCs will climb to earlier lines of treatment. Paradigms will be challenged. Here’s my list of top 10 abstracts. See you in Chicago! #bcsm

Original Article: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer (BREAKWATER phase 3 trial) nej.md/3ScDaWC #ASCO25 | ASCO

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

Wonderful to see this out in the NEJM today. Structured exercise improves survival in colon cancer! Do come to see #ChrisBooth present in hall B1 at 4 30 PM today ASCO nejm.org/doi/full/10.10…

Our meta-analysis (n=12,698) shows: Omitting 5-FU bolus from GI chemo regimens → ✔️ No difference in PFS/OS 📉 Less grade 3–4 neutropenia (OR 0.46) 📉 Less thrombocytopenia (OR 0.53) YUSUF İLHAN Yakup Ergün OncoDaily OncoAlert LARVOL

British Empire Medal Award. On the 23rd June I was asked to attend the investiture of my British Empire Medal in a truly amazing setting at Gorton Monastery in Manchester. Jeff, Regan, Faron and myself attended and we had to be there at 10:30am along with other esteemed

Fulminant Tumour Lysis Syndrome after Nivolumab and Ipilimumab treatment for Hepatocellular Carcinoma Journal of Hepatology doi.org/10.1016/j.jhep… 🧐New problems with more effective systemic therapies in HCC❗️ ESMO - Eur. Oncology EASL Education ILCA

Not enough of this sort of straight talking in Australia anymore. Love this. #energy #auspol